A phase II study (NCT03872427) that was initiated to investigate the role of CB-839 HCl, a glutaminase inhibitor, in cancer cases with specific mutations, including NF1-mutation positive MPNSTs, is still ongoing [99]. The gene discussed is NF1; the disease is cancer.